Literature DB >> 21847361

Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model.

Andreas Birbach1, David Eisenbarth, Nicolas Kozakowski, Eva Ladenhauf, Marc Schmidt-Supprian, Johannes A Schmid.   

Abstract

In prostate cancers, epidemiological data suggest a link between prostate inflammation and subsequent cancer development, but proof for this concept in a tumor model is lacking. A constitutively active version of IκB kinase 2 (IKK2), which is activated by many inflammatory stimuli, was expressed specifically in the prostate epithelium. Constitutive activation of the IKK2/nuclear factor κB axis was insufficient for prostate transformation. However, in combination with heterozygous loss of phosphatase and tensin homolog, IKK2 activation led to an increase in tumor size, formation of cribriform structures, and increase in fiber in the fibroblastic stroma. This phenotype was coupled with persistent inflammation evoked by chemokine expression in the epithelium and stroma. The hyperplastic and dysplastic epithelia correlated with changes evoked by decreased androgen receptor activation. Conversely, inflammation correlated with stromal changes highlighted by loss of smooth muscle cells around prostate ducts. Despite the loss of the smooth muscle barrier, tumors were rarely invasive in a C57BL/6 background. Data mining revealed that smooth muscle markers are also downregulated in human prostate cancers, and loss of these markers in primary tumors is associated with subsequent metastasis. In conclusion, our data show that loss of smooth muscle and invasiveness of the tumor are not coupled in our model, with inflammation leading to increased tumor size and a dedifferentiated stroma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21847361      PMCID: PMC3156660          DOI: 10.1593/neo.11524

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

2.  Epidemiologic association between prostatitis and prostate cancer.

Authors:  Leslie K Dennis; Charles F Lynch; James C Torner
Journal:  Urology       Date:  2002-07       Impact factor: 2.649

3.  T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

Authors:  A Suzuki; M T Yamaguchi; T Ohteki; T Sasaki; T Kaisho; Y Kimura; R Yoshida; A Wakeham; T Higuchi; M Fukumoto; T Tsubata; P S Ohashi; S Koyasu; J M Penninger; T Nakano; T W Mak
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

4.  NF-kappaB and TNF-alpha stimulate androgen receptor expression in Sertoli cells.

Authors:  Frank J Delfino; Jared N Boustead; Charity Fix; William H Walker
Journal:  Mol Cell Endocrinol       Date:  2003-03-28       Impact factor: 4.102

Review 5.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

6.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression.

Authors:  Donkena Krishna Vanaja; John C Cheville; Steve J Iturria; Charles Y F Young
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

7.  Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases.

Authors:  Cory Abate-Shen; Whitney A Banach-Petrosky; Xiaohui Sun; Kyriakos D Economides; Nishita Desai; Jeffery P Gregg; Alexander D Borowsky; Robert D Cardiff; Michael M Shen
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

8.  Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis.

Authors:  Y C Wong; N N C Tam
Journal:  Differentiation       Date:  2002-12       Impact factor: 3.880

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

Review 10.  Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis.

Authors:  S Mahmud; E Franco; A Aprikian
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  16 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

3.  Development of animal models underlining mechanistic connections between prostate inflammation and cancer.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  World J Clin Oncol       Date:  2013-02-10

4.  Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.

Authors:  Grant N Burcham; Gregory M Cresswell; Paul W Snyder; Long Chen; Xiaoqi Liu; Scott A Crist; Michael D Henry; Timothy L Ratliff
Journal:  Am J Pathol       Date:  2014-11-22       Impact factor: 4.307

Review 5.  Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.

Authors:  Simeng Wen; Hong-Chiang Chang; Jing Tian; Zhiqun Shang; Yuanjie Niu; Chawnshang Chang
Journal:  Am J Pathol       Date:  2014-11-26       Impact factor: 4.307

6.  PTEN deletion drives aberrations of DNA methylome and transcriptome in different stages of prostate cancer.

Authors:  Chao Wang; Yaping Feng; Chengyue Zhang; David Cheng; Renyi Wu; Yuqing Yang; Davit Sargsyan; Dibyendu Kumar; Ah-Ng Kong
Journal:  FASEB J       Date:  2019-11-29       Impact factor: 5.191

7.  15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells.

Authors:  Yunping Hu; Haiguo Sun; Joseph T O'Flaherty; Iris J Edwards
Journal:  Carcinogenesis       Date:  2012-10-11       Impact factor: 4.944

8.  Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin.

Authors:  Oh-Joon Kwon; Li Zhang; Michael M Ittmann; Li Xin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

9.  Does the microenvironment influence the cell types of origin for prostate cancer?

Authors:  Andrew S Goldstein; Owen N Witte
Journal:  Genes Dev       Date:  2013-07-15       Impact factor: 11.361

10.  Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2012-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.